Reveals of candidate active ingredients in Justicia and its anti-thrombotic action of mechanism based on network pharmacology approach and experimental validation
| Autor: | Ting Zhang, Ying Zhang, Hezhen Wu, Lu Yi, Yunfeng Yao, Yanfang Yang, Zongchao Hong, Bo Liu, Zhou-Tao Xie |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Blood Platelets
Male rac1 GTP-Binding Protein ATP Binding Cassette Transporter Subfamily B Molecular biology Computer science Science Mechanism based Drug development Computational biology Lignans Article Mice Fibrinolytic Agents Interaction network Justicia Network pharmacology Animals Humans Gene Regulatory Networks Protein Interaction Maps KEGG Inhibitory effect Cells Cultured Cyclic Nucleotide Phosphodiesterases Type 5 Active ingredient Mice Inbred BALB C Multidisciplinary Drug discovery Mechanism (biology) Dioxolanes Experimental validation Proto-Oncogene Proteins c-met Chemokine CXCL12 Computational biology and bioinformatics Matrix Metalloproteinase 9 Medicine |
| Zdroj: | Scientific Reports, Vol 11, Iss 1, Pp 1-18 (2021) Scientific Reports |
| ISSN: | 2045-2322 |
| Popis: | Thrombotic diseases seriously threaten human life. Justicia, as a common Chinese medicine, is usually used for anti-inflammatory treatment, and further studies have found that it has an inhibitory effect on platelet aggregation. Therefore, it can be inferred that Justicia can be used as a therapeutic drug for thrombosis. This work aims to reveal the pharmacological mechanism of the anti-thrombotic effect of Justicia through network pharmacology combined with wet experimental verification. During the analysis, 461 compound targets were predicted from various databases and 881 thrombus-related targets were collected. Then, herb-compound-target network and protein–protein interaction network of disease and prediction targets were constructed and cluster analysis was applied to further explore the connection between the targets. In addition, Gene Ontology (GO) and pathway (KEGG) enrichment were used to further determine the association between target proteins and diseases. Finally, the expression of hub target proteins of the core component and the anti-thrombotic effect of Justicia’s core compounds were verified by experiments. In conclusion, the core bioactive components, especially justicidin D, can reduce thrombosis by regulating F2, MMP9, CXCL12, MET, RAC1, PDE5A, and ABCB1. The combination of network pharmacology and the experimental research strategies proposed in this paper provides a comprehensive method for systematically exploring the therapeutic mechanism of multi-component medicine. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink